Original Report

Access to specialized treatment by adult Hispanic brain tumor patients: findings from a single-institution retrospective study


 

Background: The Hispanic population accounts for 15% of the population of the United States, and for as much as 75% in cities throughout California. Racial disparities that are reflected by limited access to health care and worse disease outcomes are well documented for adult Hispanic cancer patients.

Objective: To determine whether there are similar disparities—including delays in accessing surgery, radiation, and oncologic care—for adult Hispanic non English-speaking (HNES) neuro-oncology patients and white English-only–speaking (WES) patients in an academic, tertiary care center with a multidisciplinary neuro-oncology team.

Methods: This retrospective study was conducted at the Chao Family Comprehensive Cancer Center of the University of California, Irvine. All patients who were diagnosed with a primary brain tumor during January 1, 2003, to December 31, 2008, were identified and data were collected on their age, sex, ethnicity, languages spoken, diagnosis, and insurance status. The times from the date of diagnosis to the date of surgery, from the date of surgery to the date of starting radiation (if indicated), and from the date of finishing radiation to the date of starting chemotherapy (if indicated) were also recorded.

Results: Most of the HNES patients (56.4%) had state insurance for the indigent, whereas most of the WES patients (41.8%) had private insurance from a health maintenance organization. Moreover, 12.8% of HNES patients were uninsured, compared with 4.5% of WES patients. There were no significant delays in the time from diagnosis to surgery, but there was a significant delay in access to radiation treatment (P .023). There were no differences on overall survival between the 2 groups of patients.

Limitations: This is a retrospective study of a relatively small number of patients. Larger studies are needed to corroborate these findings

Conclusions: The findings demonstrate that there are disparities in insurance status and access to radiation therapy between HNES and WES neuro-oncology patients.

*To read the the full article, click on the link at the top of this introduction.

Recommended Reading

Central Nervous System Complications of Cancer Therapy
MDedge Hematology and Oncology
PET Radiotracer Identifies Glioma Treatment Response
MDedge Hematology and Oncology
FDA Warns of QT Prolongation with Ondansetron Dose
MDedge Hematology and Oncology
FDA Approves REMS for Long-Acting Opioids
MDedge Hematology and Oncology
Erlotinib Fails as Maintenance Therapy for Ovarian Cancer
MDedge Hematology and Oncology
Washington Post Blasts Proliferation of ESAs for Anemia
MDedge Hematology and Oncology
Brain Tumors Glow 'Like Lava' With New Surgical Probe
MDedge Hematology and Oncology
Treating Brain Tumors With Bacteria Gets Neurosurgeons Banned
MDedge Hematology and Oncology
Radiation Oncologists Say Medicare Cuts Could Shutter Practices
MDedge Hematology and Oncology
Labs Find Evidence of Cancer Stem Cells
MDedge Hematology and Oncology